Tissue Heart Valves Market

• The Tissue Heart Valves Devices Market represents a pivotal sector within the healthcare industry, focused on the development, manufacturing, and distribution of heart valves made from biological tissues.
• The leading companies working in the Tissue Heart Valves Market include Abbott, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, Medtronic, Sorin Group (LivaNova PLC), and others.

Tissue Heart Valves Market by Product Type (Aortic Valve, Mitral Valve, Pulmonary Valve, and Tricuspid Valve), Tissue Heart Valves Market by Type (Stented Tissue Heart Valves and Stentless Tissue Heart Valves), Tissue Heart Valves Market by End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Tissue Heart Valves Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR Forecast till 2030 owing to a rise in the demand observed for minimally invasive procedures and the rising prevalence for heart valve diseases.

The Tissue Heart Valves Market is estimated to grow at a CAGR of 7.56% during the forecast period from 2024 to 2030. The demand for tissue heart valves is primarily witnessing growth on account of the high prevalence of heart valve diseases such as aortic valve degeneration and aortic stenosis, the increase in demand for minimally invasive procedures, technological advancements of the tissue heart valves and longer life expectancy of the geriatric population.

Tissue Heart Valves Market Dynamics

The high prevalence observed in the case of heart valve diseases such as aortic valve degeneration and aortic stenosis tends to drive the tissue heart valve market. According to a research study by the European Society of Cardiology 2020, in the United States, aortic stenosis is the second most frequent valvular lesion.  At the age of 65, it affects roughly 5% of the population, with the prevalence increasing with age. The study also revealed Europe, the United States, and Taiwan discovered a population prevalence of aortic stenosis of 12.4% and a prevalence of severe AS of 3.4% in individuals 75 and older.

The growing preference for minimally invasive procedures associated with making minimum surgical incisions, and lesser risks of bleeding and infection among other complications coupled with rising technological advancements to develop comparatively safer and effective Tissue Heart Valves for patients with heart valve diseases is majorly boosting the market of these devices.

However, stringent product approval processes and the high cost associated with minimally invasive procedures are expected to limit the market growth over the forecast period.

Tissue Heart Valves Market Segment Analysis

Tissue Heart Valves Market by Product Type (Aortic Valve, Mitral Valve, Pulmonary Valve, and Tricuspid Valve), Tissue Heart Valves Market by Type (Stented Tissue Heart Valves and Stentless Tissue Heart Valves), Tissue Heart Valves Market by End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Tissue Heart Valves Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the Tissue heart valves device type segment, the stentless segment is expected to achieve a larger market share during the forecast period.

The stentless tissue valves tend to offer advantages over the stented tissue valves such as a reduction in the rate of thrombosis and superior hemodynamics. The structure offered by the stentless valve prostheses is designed for achieving a more physiological flow pattern when compared with the stented valves.

Apart from this in several studies, it has been reported that the stentless valves allow an improved postoperative coronary flow after valve replacement for aortic stenosis.

The stentless aortic root bio-prosthesis, the full root versus sub-coronary implantation offered better early transvalvular gradients, effective orifice area, and left ventricular mass regression as well as late freedom from structural valve deterioration in many retrospective studies. Patients suffering from aortic stenosis and other valvular diseases will be more inclined towards the stentless tissue heart valves in contrast to the stented heart tissue valves because of the various benefits offered by them.

Due to the several advantages that stentless tissue valves have to offer over stented tissue valves, their demand will surely experience a surge in the market, thereby leading to an increase in the market of stentless tissue heart valves.

North America is expected to dominate the overall Tissue Heart Valves Market:

Among all the regions, North America Tissue Heart Valves Market is expected to account for the largest share in the Tissue Heart Valves market. the increase in the prevalence of valvular heart diseases, the favorable reimbursement scenario of tissue heart valves, and the rising product approvals for tissue heart valves are predicted to be the major influencing factors in driving the overall growth of the market over the forecast period.

According to the Centers for Disease Control and Prevention, 2019, almost 2.5% of the US population has valvular heart disease, but it is more common in older adults. Rheumatic heart disease tends to affect most commonly the mitral valve or the aortic valve, however, any valve can be affected and more than one valve can be involved. Approximately 25,000 deaths in the United States each year are due to heart valve disease from causes other than rheumatic disease. The bicuspid aortic valve happens in about 1% to 2% of the population and is mostly common among men. Due to the rise in the number of patients suffering from valvular diseases, the demand for tissue heart valve replacements will increase, thereby driving the Tissue Heart Valves market.

The rise in product approvals has also driven the Tissue Heart Valves market in the US. For example, in May 2022, the US FDA approved Edwards Lifesciences LLC Company’s Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve System, for use when the mitral valve fails and the patient has a prosthetic ring implanted around the mitral valve to help keep the shape.

Therefore, the above-mentioned factors are going to bolster the North America Tissue Heart Valves markets.

Tissue Heart Valves Companies

Some of the key Tissue Heart Valves companies operating in the Tissue Heart Valves market include Abbott, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, Medtronic, Sorin Group (LivaNova PLC), Braile Biomédica and Labcor Laboratórios, Colibri Heart Valve, ON-X LIFE TECHNOLOGIES, INC., JenaValve Technology Inc., TTK Healthcare Limited, Comed BV, Meril Life Sciences Pvt. Ltd., Beijing Balance Medical Technology Co., Ltd, Venus Medtech and others.

Recent Developmental Activities in the Tissue Heart Valves Market:

• In September 2020, the leading transcatheter heart valve medical device player in China announced their joint venture with Jilin Changchun Haoyue Halal Meat Co., Ltd ("Haoyue Group"). Venus Medtech and Venus Haoyue Medtech aim to provide total treatment solutions for heart valve diseases from the source of biomaterials.

Key Takes Away from the Tissue Heart Valves Market Report Study

• Tissue Heart Valves Market size analysis for current market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key Tissue Heart Valves companies dominating the Global Tissue Heart Valves Market.
• Various opportunities available for the other competitors in the Tissue Heart Valves Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current market scenario?
• Which are the regions and countries where Tissue Heart Valves manufacturers should have concentrated on opportunities for market growth in the coming future?

Target Audience Who Can be benefited from the Tissue Heart Valves Market Report Study

• Tissue Heart Valve providers
• Research organizations and consulting Tissue Heart Valves companies
• Tissue Heart Valves-related organization, association, forum, and other alliances
• Government and corporate offices
• Start-up Tissue Heart Valves manufacturers, venture capitalists, and private equity firms
• Distributors and Traders
• Various End-Users who want to know more about the Tissue Heart Valves Market and the latest technological developments in the Tissue Heart Valves market.

For More In-depth Information @ Latest DelveInsight Blog